Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition for treating radiation proctitis

A composition and drug technology, applied in directions such as drug combination, drug delivery, and pharmaceutical formula, can solve the problems of not disclosing the dosage and ratio of various ingredients, not providing formula experimental data and effect verification, etc., and achieving a short drug action time. , Improve the local cell microenvironment and limit the effect of damage expansion

Inactive Publication Date: 2016-04-13
官键
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, this invention patent application only lists the above-mentioned various raw materials, but does not disclose the dosage and proportion of various ingredients
The invention patent application also did not provide experimental data and effect verification for the formula

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for treating radiation proctitis
  • Pharmaceutical composition for treating radiation proctitis
  • Pharmaceutical composition for treating radiation proctitis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] Embodiment 1: the preparation of drug compound

[0027] The raw materials used in this example are: 10 g of sucralfate, 0.1 g of lidocaine, 5 mg of dexamethasone, 80,000 units of gentamicin, 10,000 units of recombinant epidermal growth factor and 100 ml of normal saline.

[0028] Sucralfate can use the existing commercial product "Sucralfate Suspension", the specification is 10ml / cartridge, the effective content is 1g / cartridge, and a total of 10 sticks are used.

[0029] The lidocaine can adopt the existing commercial product "lidocaine hydrochloride", the specification is 5ml each, the effective dose is 1g, and a total of one is used.

[0030] Dexamethasone can use the existing commercial product "Dexamethasone Sodium Phosphate Injection", the specification is 1ml each, containing dexamethasone 5mg, a total of 1 bottle is used.

[0031] Gentamicin can use the existing commercial product "Gentamycin Injection", the specification is 2ml per vial, containing 80,000 unit...

Embodiment 2

[0034] Embodiment 2: the use method of drug compound

[0035] The above-mentioned drug complex is placed in an enema bag, and the temperature of the liquid is controlled at about 40 degrees Celsius. The patient lies on the left side, the anus of the enema bag is short and gently inserted into the anal canal, the insertion depth is 20-25cm, the infusion switch is turned on, and the flow rate is controlled at 60-80 drops per minute. After the infusion, the patient kept the left side lying position for 30 minutes and then returned to the supine position, keeping the enema solution for as long as possible.

Embodiment 3

[0036] Embodiment 3: the clinical application effect of drug compound

[0037] 1. Subject selection

[0038] Diagnostic criteria: Select patients with a history of radiotherapy for abdominal and pelvic tumors in the past, and patients with late rectal reactions such as difficulty in defecation, thin or frequent defecation, loose stools, blood in the stool, and falling pain during defecation. According to the National Occupational Health Standard of the People's Republic of China "Diagnostic Criteria for Radiation Proctitis" GBZ111-2002, it was diagnosed as radiation proctitis.

[0039] Inclusion criteria: a history of radiation therapy for pelvic tumors; age: 18-75 years old; male or female; hospitalized patients; agree to participate in this trial and sign an informed consent form

[0040] Exclusion criteria: Pregnant women; patients with acute abdomen; patients with anus, rectum, and contact surgery; patients with fecal incontinence; brain diseases, abnormal judgment abilit...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a pharmaceutical composition for treating radiation proctitis. The pharmaceutical composition for treating the radiation proctitis consists of the following components: sucralfate, lidocaine, dexamethasone, gentamicin and a recombinant human epidermal growth factor. The invention also provides application of the pharmaceutical composition in preparing a solution preparation for retention enema. The invention provides a pharmaceutical composition, which is low in toxic and side effects, concrete in curative effect, rapid to take effect, cheap and convenient, for treating patients with the radiation proctitis; and the pharmaceutical composition is capable of improving the life quality of the patients and guaranteeing the smooth implementation of the radiotherapy.

Description

technical field [0001] The invention belongs to the field of pharmaceutical formulations, in particular to a pharmaceutical composition for treating radiation proctitis. Background technique [0002] Radiation therapy is an important treatment for abdominal and pelvic malignant tumors such as cervical cancer, rectal cancer, and prostate cancer. Radiation proctitis is a complication that often occurs after radiation therapy for pelvic and abdominal malignant tumors. At present, with the increasing incidence of pelvic and abdominal malignant tumors and the wide application of radiotherapy techniques, the incidence of radiation proctitis is also on the rise. According to reports, the incidence of radiation proctitis caused by radiotherapy ranges from 6.4% to 21.6%. The common clinical manifestations of radiation enteritis include chronic abdominal pain, increased stool frequency, mucus stool, bloody stool, rectal pain and tenesmus, etc. The condition is more complicated, and m...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/18A61K9/08A61P1/00A61K31/7024A61K31/167A61K31/573A61K31/7036
CPCA61K31/167A61K9/0031A61K9/08A61K31/573A61K31/7036A61K33/08A61K38/18A61K2300/00
Inventor 官键
Owner 官键
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com